argenx SE (NASDAQ:ARGX) Shares Acquired by Quadrant Capital Group LLC

Quadrant Capital Group LLC lifted its stake in shares of argenx SE (NASDAQ:ARGX) by 5.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,120 shares of the company’s stock after buying an additional 54 shares during the period. Quadrant Capital Group LLC’s holdings in argenx were worth $689,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Whipplewood Advisors LLC purchased a new position in argenx in the 4th quarter worth $37,000. Global Retirement Partners LLC raised its stake in shares of argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after purchasing an additional 48 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of argenx by 1,016.7% during the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after purchasing an additional 61 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its position in argenx by 78.6% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock valued at $46,000 after buying an additional 33 shares during the last quarter. Finally, Huntington National Bank increased its holdings in argenx by 1,133.3% in the 4th quarter. Huntington National Bank now owns 74 shares of the company’s stock worth $46,000 after buying an additional 68 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ARGX has been the subject of several research reports. Piper Sandler lifted their price objective on shares of argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research note on Tuesday, January 7th. Guggenheim lifted their price objective on argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a research note on Monday, March 10th. Oppenheimer upped their target price on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Robert W. Baird lifted their price target on argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research report on Tuesday, March 4th. Finally, William Blair reaffirmed an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $687.00.

argenx Stock Down 5.9 %

Shares of NASDAQ ARGX opened at $555.11 on Monday. The firm has a 50-day simple moving average of $621.43 and a 200-day simple moving average of $603.70. The stock has a market capitalization of $33.73 billion, a price-to-earnings ratio of -630.81 and a beta of 0.60. argenx SE has a 52 week low of $352.77 and a 52 week high of $678.21.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. The company had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, equities research analysts expect that argenx SE will post 3.13 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.